| Symbol | OCS |
|---|---|
| Name | OCULIS HOLDING AG |
| Sector | HEALTH CARE |
| Region | Europe |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Address | Switzerland |
| Telephone | 617-937-2423 |
| Fax | — |
| — | |
| Website | https://www.oculis.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001953530 |
| Description | Oculis Holding AG is a Switzerland-based company primally engaged in biotechnology sector. The Company is focused on the development of eye disease treatment for ophthalmology. It includes OCS-01, based on the OPTIREACH technology, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED) in a form of a single chain antibody fragment; and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and for other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The Company have operations in the USA, Europe and China. Ocullis deliver treatments to patients worldwide. Additional info from NASDAQ: |
Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities
Read moreOculis Signs Asset Purchase Agreement with Accure Therapeutics for Lead Candidate, Privosegtor, Fortifying Oculis’ Position as an Emerging Leading Neuro-Ophthalmology Company
Read moreOculis undirritar kaupsamning við Accure Therapeutics um leiðandi þróunarlyfið Privosegtor og eflir þannig stöðu Oculis sem leiðandi vaxtarfyrirtækis á sviði taugaaugnlækninga
Read moreOculis Signs Asset Purchase Agreement with Accure Therapeutics for Lead Candidate, Privosegtor, Fortifying Oculis’ Position as an Emerging Leading Neuro-Ophthalmology Company
Read moreOculis birtir uppgjör fyrir annan ársfjórðung 2026 og kynnir áfanga í rekstri félagsins
Read moreOculis Announces Positive FDA Pre-IND Feedback Supporting Privosegtor Development Strategy for Treatment of Acute Multiple Sclerosis Relapses
Read moreOculis Announces Positive FDA Pre-IND Feedback Supporting Privosegtor Development Strategy for Treatment of Acute Multiple Sclerosis Relapses
Read moreOculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities
Read more